Keyphrases
Heme
100%
Immune Checkpoint Blockade
100%
Hematological Complications
100%
IrAE
100%
Immune Checkpoint Inhibitors
40%
Time to Onset
20%
Johns Hopkins Hospital
20%
T Cells
20%
Autoimmune Response
20%
Malignancy
20%
Immune Response
20%
Median Time
20%
Thrombocytopenia
20%
Cell-to-cell
20%
B Cells
20%
Case Fatality Rate
20%
Programmed Death-ligand 1 (PD-L1)
20%
Hematologic
20%
Treatment Algorithm
20%
Hemolytic Anemia
20%
Immune Thrombocytopenia
20%
Treatment Alternatives
20%
Aplastic Anemia
20%
Immune-related Adverse Events
20%
Substantial Clinical Benefit
20%
Agranulocytosis
20%
Steroid-refractory
20%
CTLA-4 Inhibitors
20%
Self-tolerance
20%
Refractory Cases
20%
Nivolumab
20%
Anti-PD-1
20%
Medicine and Dentistry
Heme
100%
Immune Checkpoint Blockade
100%
Immune Checkpoint Inhibitor
40%
Recurrent Disease
20%
Prevalence
20%
Mortality Rate
20%
Cancer
20%
T Cell
20%
Idiopathic Thrombocytopenic Purpura
20%
Thrombocytopenia
20%
Hemolytic Anemia
20%
B Cell
20%
Aplastic Anemia
20%
Immunological Tolerance
20%
CTLA-4
20%
Immune-Related Adverse Events
20%
Autoimmunity
20%
Programmed Death-Ligand 1
20%
Nivolumab
20%
Agranulocytosis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Heme
100%
Immune Checkpoint Inhibitor
40%
Adverse Event
20%
Prevalence
20%
Recurrent Disease
20%
Thrombocytopenia
20%
Mortality Rate
20%
Idiopathic Thrombocytopenic Purpura
20%
Hemolytic Anemia
20%
Aplastic Anemia
20%
Cytotoxic T Lymphocyte Antigen 4
20%
Agranulocytosis
20%
Nivolumab
20%